Drugs / Seraprevir
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04111367 | Apr 2019 → Apr 2020 | hepatitis C virus infection | Ginkgopharma CO., LTD | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04001608 | Oct 2018 → Jul 2019 | hepatitis C virus infection | Ginkgopharma CO., LTD | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Seraprevir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04001608 ↗ |
| Route | Oral | “oral tablets of Seraprevir 100 mg” NCT04001608 ↗ |